Bio-Rad Launches Antiphospholipid Syndrome IgG, IgM, and IgA Kits for its BioPlex 2200 System

Bio-Rad Laboratories, Inc. has announced the European and Canadian launch of its BioPlex® 2200 Antiphospholipid Syndrome IgG, IgM, and IgA kits for use on its BioPlex® 2200 system.

Antiphospholipid Syndrome is an autoimmune disease in which the body's immune system mistakenly produces antibodies to certain blood proteins causing thrombosis (clotting) within arteries, veins, and small blood vessels.

Patients with Antiphospholipid Syndrome are at risk of strokes and heart attacks. In addition, thrombosis within arteries and veins has the potential to affect other organs such as the lungs, liver, and kidney.

The BioPlex 2200 Antiphospholipid Syndrome IgG, IgM, and IgA kits are used as an aid in the diagnosis of this disease by simultaneously detecting two autoantibodies (anti-Cardiolipin and anti-Beta-2 Glycoprotein I) and therefore leading to faster and better care for those suffering from this syndrome.

"The release of the Antiphospholipid Syndrome reflects our continued commitment to expand our menu around the BioPlex 2200 testing system," said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics.

Goetz continued, "By obtaining multiplex results from a single patient sample, laboratories and physicians can get the answers they need to provide faster and more effective patient treatment."

The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system and provides clinical laboratories with the capability to rapidly process or "multiplex" multiple individual tests, which are traditionally processed separately, using a single small volume patient sample.